John A. Eden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John A. Eden has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
A. Ekangaki
Sydney Menopause Centre, Royal Hospital for Women, Barker Street, Randwick, NSW, 2031, Australia
1 shared publicationAbie Ekangaki
School of Women and Children's Health, University of New South Wales, Royal Hospital for Women, Randwick, New South Wales, Australia
1 shared publicationK.E. Willetts
Natural Therapies Unit, Royal Hospital for Women, Randwick, Australia
1 shared publicationKaren E. Willetts
School of Women and Children's Health, University of New South Wales, Royal Hospital for Women, Randwick, New South Wales, Australia
1 shared publicationM.S. Clements
Cancer Research Council, NSW
1 shared publicationMichael Fortune
Prince of Wales Private Hospital, Sydney, NSW
1 shared publication
Latest Publications
- Open Access
- 30 April 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (5) , 427-431
Why does hormonal contraception and menopausal hormonal treatment have such a small effect on breast cancer risk?
Oestrogen is considered by many to be a major cause of breast cancer, and yet hormonal contraception and menopausal hormonal therapy have a paradoxically small effect on breast cancer risk. Also, in the oestrogen‐only arm of the Women's Health Initiative, subjects given oestrogen had a reduced risk of breast cancer compared to controls. Initiation of breast cancer likely begins early in life, in the long‐lived ER−PR− breast stem cell. The main mitogen of ER+PR+ breast cancers is oestrogen derived from local breast fat and the tumour itself, rather than circulating oestrogens. Progesterone is relatively breast neutral, but progestins in the laboratory have been shown to expand malignant breast stem cell number.
- 30 April 2024
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 64 (5) , 427-431
Open AccessWhy does hormonal contraception and menopausal hormonal treatment have such a small effect on breast cancer risk?
Oestrogen is considered by many to be a major cause of breast cancer, and yet hormonal contraception and menopausal hormonal therapy have a paradoxically small effect on breast cancer risk. Also, in the oestrogen‐only arm of the Women's Health Initiative, subjects given oestrogen had a reduced risk of breast cancer compared to controls. Initiation of breast cancer likely begins early in life, in the long‐lived ER−PR− breast stem cell. The main mitogen of ER+PR+ breast cancers is oestrogen derived from local breast fat and the tumour itself, rather than circulating oestrogens. Progesterone is relatively breast neutral, but progestins in the laboratory have been shown to expand malignant breast stem cell number.
- 1 February 2017
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 57 (1) , 12-15
The endometrial and breast safety of menopausal hormone therapy containing micronised progesterone: A short review
For a significant minority of women, menopausal symptoms can be very unpleasant; however, many are worried about taking menopausal hormone therapy (MHT) for fear of causing breast cancer. Micronised progesterone (mP4) has been available in Europe since the 1990s and clinical trials have shown that 100 mg oral daily, 200 mg oral sequentially or 100 mg vaginal every second day effectively protect the endometrium from the stimulatory effects of oestrogen. MHT containing mP4 has a significantly lower breast cancer risk than those containing progestins. Micronised progesterone does not appear to attenuate the cardiovascular benefits of oestrogen. Pharmaceutical grade, body identical MHT is now available in Australia.
- 1 February 2017
- Published by Wiley in Australian and New Zealand Journal of Obstetrics and Gynaecology
- Vol. 57 (1) , 12-15
The endometrial and breast safety of menopausal hormone therapy containing micronised progesterone: A short review
For a significant minority of women, menopausal symptoms can be very unpleasant; however, many are worried about taking menopausal hormone therapy (MHT) for fear of causing breast cancer. Micronised progesterone (mP4) has been available in Europe since the 1990s and clinical trials have shown that 100 mg oral daily, 200 mg oral sequentially or 100 mg vaginal every second day effectively protect the endometrium from the stimulatory effects of oestrogen. MHT containing mP4 has a significantly lower breast cancer risk than those containing progestins. Micronised progesterone does not appear to attenuate the cardiovascular benefits of oestrogen. Pharmaceutical grade, body identical MHT is now available in Australia.
- 1 March 2016
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 174 (3) , R71-R77
ENDOCRINE DILEMMA: Managing menopausal symptoms after breast cancer
Managing the symptoms of menopause after a diagnosis of breast cancer offers some unique clinical challenges. For some women, vasomotor symptoms can be severe and debilitating, and hormone therapy is at least relatively contraindicated. Non-oestrogen therapies for hot flushes include SSRIs, clonidine, gabapentin and perhaps black cohosh extracts. Vulvovaginal atrophy can usually be alleviated by simple moisturizers, although some may need specialized physiotherapy such as vaginal dilators. In a small number, topical oestrogens may be the only treatment that works. The CO2laser may be a novel, non-oestrogen therapy to alleviate this unpleasant symptom. Bone loss can be accelerated in some patients on AIs or those who had early menopause induced by chemotherapy.
- 1 March 2016
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 174 (3) , R71-R77
ENDOCRINE DILEMMA: Managing menopausal symptoms after breast cancer
Managing the symptoms of menopause after a diagnosis of breast cancer offers some unique clinical challenges. For some women, vasomotor symptoms can be severe and debilitating, and hormone therapy is at least relatively contraindicated. Non-oestrogen therapies for hot flushes include SSRIs, clonidine, gabapentin and perhaps black cohosh extracts. Vulvovaginal atrophy can usually be alleviated by simple moisturizers, although some may need specialized physiotherapy such as vaginal dilators. In a small number, topical oestrogens may be the only treatment that works. The CO2laser may be a novel, non-oestrogen therapy to alleviate this unpleasant symptom. Bone loss can be accelerated in some patients on AIs or those who had early menopause induced by chemotherapy.
- 11 April 2013
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 14 (2) , 57-63
Menopausal status, adipose tissue, and breast cancer risk: impact of estrogen replacement therapy
The seeds of breast cancer are likely sown in the first two or three decades of life. Rapid weight gain and height in infancy predict breast cancer risk in later life. The age at first pregnancy is also a strong predictor for breast cancer; the earlier the first full-term pregnancy, then the lower the risk of breast cancer in later life. It has been postulated that the breast stem cell number may be the factor linking these observations together. Menopause, per se, is associated with an increase in central adiposity, which is reversed by hormone replacement usage. Breast and nonbreast fat both produce estrogens and cytokines that may promote the growth of small breast cancers making them appear earlier. Obesity also is associated with metabolic syndrome, which is a risk factor for breast cancer. The breast cancer stem cells make up only around 1%–2% of the tumor mass and, yet, are the likely driver for much of a breast cancer’s behavior. Future research into breast cancer biology, especially into the cancer stem cells is likely to translate into novel methods of treatment and prevention of this common cancer.
- 11 April 2013
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 14 (2) , 57-63
Menopausal status, adipose tissue, and breast cancer risk: impact of estrogen replacement therapy
The seeds of breast cancer are likely sown in the first two or three decades of life. Rapid weight gain and height in infancy predict breast cancer risk in later life. The age at first pregnancy is also a strong predictor for breast cancer; the earlier the first full-term pregnancy, then the lower the risk of breast cancer in later life. It has been postulated that the breast stem cell number may be the factor linking these observations together. Menopause, per se, is associated with an increase in central adiposity, which is reversed by hormone replacement usage. Breast and nonbreast fat both produce estrogens and cytokines that may promote the growth of small breast cancers making them appear earlier. Obesity also is associated with metabolic syndrome, which is a risk factor for breast cancer. The breast cancer stem cells make up only around 1%–2% of the tumor mass and, yet, are the likely driver for much of a breast cancer’s behavior. Future research into breast cancer biology, especially into the cancer stem cells is likely to translate into novel methods of treatment and prevention of this common cancer.
- 6 September 2011
- Published by Springer Nature
- p. 231-240
Breast Cancer Risk: Role of Somatic Breast Stem Cells
- 6 September 2011
- Published by Springer Nature
- p. 231-240
Breast Cancer Risk: Role of Somatic Breast Stem Cells
- 1 July 2010
- Published by Wolters Kluwer Health in Menopause
- Vol. 17 (4) , 801-810
Human breast cancer stem cells and sex hormones-a narrative review
The aim of this narrative review was to evaluate the role of cancer stem cells (CSCs) and sex steroids in the pathophysiology of human breast cancer. A key-word search was performed using the Scopus database. Preference was given to studies using human cells and tissues. Long-term estrogen-progestin hormone therapy is known to increase breast cancer risk, although the mechanisms are poorly understood. In the last few years, it has become clear that many human breast cancers contain CSCs, which may be responsible for much of the tumor's malignant behavior. Very recently, the impact of estrogen, progesterone, and progestins on breast CSCs and their progeny has been studied and clarified. Most breast CSCs are estrogen receptor negative and progesterone receptor negative, although some intermediary progenitor forms have hormone receptors, especially progesterone receptor. Most mature human breast cancer cellsare estrogen receptor positive and can thus be stimulated by estrogen. Breast CSCs usually elaborate CD44+,CD24j/low and/or ALDEFLUOR+ cell markers and are lineage markers negative. One of the main roles of progesterone and progestin seems to be on certain breast cancer stem intermediate forms, inducing them to revert back to a more primitive breast CSC form. As the pathophysiology of human breast CSC is clarified, it is probable that this will lead to novel, effective breast cancer treatments and, perhaps, new breast cancer preventive agents. This research may also lead to safer hormone therapy regimens.
- 1 July 2010
- Published by Wolters Kluwer Health in Menopause
- Vol. 17 (4) , 801-810
Human breast cancer stem cells and sex hormones-a narrative review
The aim of this narrative review was to evaluate the role of cancer stem cells (CSCs) and sex steroids in the pathophysiology of human breast cancer. A key-word search was performed using the Scopus database. Preference was given to studies using human cells and tissues. Long-term estrogen-progestin hormone therapy is known to increase breast cancer risk, although the mechanisms are poorly understood. In the last few years, it has become clear that many human breast cancers contain CSCs, which may be responsible for much of the tumor's malignant behavior. Very recently, the impact of estrogen, progesterone, and progestins on breast CSCs and their progeny has been studied and clarified. Most breast CSCs are estrogen receptor negative and progesterone receptor negative, although some intermediary progenitor forms have hormone receptors, especially progesterone receptor. Most mature human breast cancer cellsare estrogen receptor positive and can thus be stimulated by estrogen. Breast CSCs usually elaborate CD44+,CD24j/low and/or ALDEFLUOR+ cell markers and are lineage markers negative. One of the main roles of progesterone and progestin seems to be on certain breast cancer stem intermediate forms, inducing them to revert back to a more primitive breast CSC form. As the pathophysiology of human breast CSC is clarified, it is probable that this will lead to novel, effective breast cancer treatments and, perhaps, new breast cancer preventive agents. This research may also lead to safer hormone therapy regimens.